We are a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders.
Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our pharmaceutical collaborators – a novel product pipeline of ion channel modulators to address therapeutic areas of high unmet medical need, such as pain and epilepsy.
On May 15, 2018, we hosted a webcast providing an overview of our XEN1101 and XEN901 presentations at the 14th Eilat meeting in Madrid, Spain. You can access a replay of the live webcast and download slides.Read More
Xenon Announces At-The-Market Equity Offering
July 12, 2018